聯泓新科(003022.SZ)與長春應化所開展技術合作 投建5萬噸/年PPC工業化生產線項目
格隆匯12月24日丨聯泓新科(003022.SZ)公佈,為進一步實現生物可降解材料領域戰略佈局,公司與中國科學院長春應用化學研究所於近日簽署了《合作研發基於第四代催化劑的二氧化碳基生物可降解材料(PPC)超臨界聚合工業化技術合作協議》,就共同開發基於多核鋅系催化劑(簡稱“第四代催化劑”)的聚碳酸亞丙酯(簡稱“PPC”)超臨界聚合工業化技術,雙方同意開展全面技術合作,並由控股子公司聯泓格潤(山東)新材料有限公司建設5萬噸/年PPC工業化生產線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.